BRIEF-Fulgent Genetics Q4 Revenue USD 83.336 Million
FLGT sits 61% above its 52-week low of $14.57 on elevated volume (3.0× avg).
Summary
Fulgent Genetics reported Q4 revenue of $83.336 million. The company also disclosed negative profitability metrics, including an operating income of -$36.238 million, a pretax profit of -$29.274 million, and adjusted EBITDA of -$4.5 million. These results indicate significant operational challenges and a decline in profitability, which is a material concern for investors. The negative financial performance could put downward pressure on the stock. Traders will be closely watching for further details from the company's full earnings report and any forward guidance regarding their strategy to improve profitability.
At the time of this announcement, FLGT was trading at $23.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $765.4M. The 52-week trading range was $14.57 to $31.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.